Research News

Real World Health Care talks with Diane Bovenkamp, Ph.D., Scientific Program Officer for BrightFocus Foundation, about the basic science and therapeutic research the Foundation is funding.

Research funded by BrightFocus Foundation could lead to new drugs and therapies that prevent vision loss in glaucoma more effectively than pressure-lowering treatments alone.

Time magazine recently described a “cocktail” approach to fighting Alzheimer’s. BrightFocus-funded research supports this effort, which takes us closer to a cure.

Stacy Pagos Haller, BrightFocus Foundation's President and CEO, urges the Food and Drug Administration to strongly support expanded use of neurodiagnostic tools to assess cognitive function.

Download the fall edition of our macular degeneration research newsletter and read about new treatments that are on the horizon, the latest research grants awarded for pioneering macular degeneration research, the first-ever bionic eye for patients with macular degeneration, and more.

In a major scientific breakthrough, a drug used to treat Parkinson’s and related diseases may be able to delay or prevent age-related macular degeneration (AMD), the most common form of blindness among older Americans.

A research team, supported in part by BrightFocus Foundation, wanted to know whether patients who received the drug L-DOPA as treatment for Parkinson’s or other diseases were protected from AMD. After combing through massive amounts of medical chart data, their answer is yes.

Research by BrightFocus grantee Matthew Campbell, PhD, of Trinity College Dublin, represents a potential new way to help clear the brain of a build-up of the toxic amyloid beta (Aβ) that leads to Alzheimer’s.

Researchers funded by BrightFocus Foundation are bringing us closer to preventing the spread of Alzheimer’s disease in the brain. Learn more about this exciting research.